my personal edition > congestive heart failure > news
E-Mail this DGReview to a colleague
DGReview
Salmeterol Improves Pulmonary Function In Heart Failure Patients
A DGReview of :"Chronically Inhaled Salmeterol Improves Pulmonary Function in Heart Failure"
Journal of Cardiovascular Pharmacology
07/31/2002
By James Adams
Chronically inhaled salmeterol improves pulmonary function in patients with heart failure.
It improves forced expiratory volume in one second (FEV1) without affecting neuroactivation or ventricular ectopy, investigators report.
They also report a minor increase in rate-pressure product with chronically inhaled salmeterol therapy. However, the clinical significance of this remains to be determined.
The investigators, from the Departments of Pharmacy Practice and Internal Medicine at the University of Utah Health Sciences Center in Salt Lake City, Utah, United States, conducted a prospective, randomized crossover study that included eight symptomatic heart failure patients.
Patients had a left ventricular ejection fraction below 40 percent and FEV1 less than or equal to 80 percent.
Chronic inhaled salmeterol therapy was delivered at a rate of 84 micrograms every 12 hours for 14 days. Its effects were compared with placebo in a cross over fashion.
Results showed that the therapy caused a significant, 6 percent improvement in FEV1. Salmeterol therapy resulted in an FEV1 of 2.46 ± 0.73 liters compared with 2.33 ± 0.73 with placebo.
Rate-pressure product also increased by five percent with salmeterol, but there was no increase in plasma norepinephrine, epinephrine, plasma renin activity or ventricular ectopy.
Forced vital capacity, forced expiratory flow and peak expiratory flow rates were similar with chronic inhaled salmeterol or placebo.
J Cardiovasc Pharmacol 2002; 40(1): 140-145.
"Chronically Inhaled Salmeterol Improves Pulmonary Function in Heart Failure"
All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.
| 
